share_log

Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $15 Price Target

Benzinga ·  Dec 6 00:37  · Ratings

Aegis Capital analyst David Bouchey reiterates Sunshine Biopharma (NASDAQ:SBFM) with a Buy and maintains $15 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment